Phase I, II and III trials of autologous HSPPC-gp96 vaccination in human melanoma, renal carcinoma, glioblastoma and colon carcinoma have demonstrated that immunisation elicits tumour-specific immune responses. Here, HSP90B1 is linked to neoplasm.